Try searching for...
Dr Alex Davis
B.Sci(Hons), MBBS, FRACP
For patients/carers
For doctors
B.Sci(Hons), MBBS, FRACP
Locations
Clinical interests
- Lung cancer
Languages
Fluent
- English
Biography
Clinical interest in thoracic malignancies and clinical trials.
Dr Alex Davis is a medical oncologist with a clinical interest in thoracic malignancies and clinical trials. He is an active collaborator in the Royal North Shore Lung Cancer MDT and sees patients at GenesisCare North Shore and the Northern Sydney Cancer Centre.
After starting his medical oncology training at Royal North Shore Hospital he then completed a fellowship in Thoracic Oncology at the Chris O’Brien Lifehouse. He is currently enrolled in a PhD in improving outcomes in KRAS mutant lung cancer at the University of Sydney.
He has a clinical interest in thoracic malignancy and using evidenced based practice to deliver personalised care for each patient he sees. He has a strong interest in clinical trials for improving cancer research and clinical options for patients.
More information
- Medical Oncology Group of Australia (MOGA)
- Thoracic Oncology Group of Australia (TOGA)
- European Society of Medical Oncology (ESMO)
- American Society of Clinical Oncology (ASCO)
Davis, A. P., Boyer, M., Lee, J. H., & Kao, S. C. (2020). COVID-19: the use of immunotherapy in metastatic lung cancer. Immunotherapy, 12(8), 545-548.
Davis, A., Mahar, A., Wong, K., Barnet, M., & Kao, S. (2021). Prolonged disease control on nivolumab for primary pulmonary NUT carcinoma. Clinical Lung Cancer, 22(5), e665-e667.
Davis, A. P., Kao, S. C., Clarke, S. J., Boyer, M., & Pavlakis, N. (2021). Emerging biological therapies for the treatment of malignant pleural mesothelioma. Expert Opinion on Emerging Drugs, 26(2), 179-192.
Davis, A., Clarke, S., Ayesa, S., & Chan, D. L. (2021). Market improvement in hyperammonaemic encephalopathy from multimodal treatment of metastatic neuroendocrine tumour. BMJ Case Reports CP, 14(6), e241191.
Davis, A. P., Cooper, W. A., Boyer, M., Lee, J. H., Pavlakis, N., & Kao, S. C. (2021). Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations. Immunotherapy, 13(11), 941-952.
